Developer docs
API playgroundTry for free, no card

Search company profiles

Xenon Pharmaceuticals

Full company profile

uuid0000z5y

Namestring
Xenon Pharmaceuticals
Legal namestring
Xenon Pharmaceuticals Inc.
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for neurological and psychiatric disorders. Founded in 1996 and headquartered in Burnaby, British Columbia, with a U.S. office in Needham, Massachusetts, the company trades on NASDAQ under the ticker XENE following its 2014 U.S. IPO. Xenon leverages decades of research in human genetics and ion channel biology to develop a pipeline of small molecule modulators targeting potassium (KV7) and sodium (NaV) channels in the central and peripheral nervous systems.

The company's lead product candidate is azetukalner (XEN1101), a novel, potent KV7 potassium channel opener currently in Phase 3 clinical trials across multiple indications including focal onset seizures (X-TOLE2/X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2/X-NOVA3), and bipolar depression (X-CEED). Positive Phase 3 X-TOLE2 results announced in March 2026 demonstrated 53.2% median reduction in monthly seizure frequency at the 25mg dose versus 10.4% for placebo, positioning azetukalner as a potential first-in-class potassium channel opener among antiseizure medications. The early-stage pipeline includes XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain) in Phase 1, plus the partnered program NBI-921355 (NaV1.2/1.6 inhibitor) developed with Neurocrine Biosciences.

As a pre-commercial company, Xenon does not yet generate product revenue and funds operations through equity financings. Cumulative disclosed public offerings total over $1.7 billion across 2021–2026, most recently a $747.5 million upsized offering in March 2026 that valued the company at approximately $5.3 billion. The planned FDA New Drug Application submission in Q3 2026 is the binary catalyst for transitioning to commercial revenue, supported by an active commercial infrastructure buildout including a Chief Commercial Officer (June 2025), Chief Financial Officer (October 2025), and Chief Operating Officer (August 2024). Distribution is expected to flow through specialty pharmacies, hospital buying groups, and retail networks, with Medical Science Liaisons engaging epileptologists and psychiatrists ahead of launch.

Short descriptiontext

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders, with lead candidate azetukalner in Phase 3 trials for epilepsy and depression ahead of a planned 2026 FDA submission.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBurnaby, Canada
HQ citystring
Burnaby
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroscience drug development, ion channel modulators, epilepsy therapeutics, potassium channel openers, central nervous system pharmaceuticals
Industry1 code
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neurology Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue company. Once azetukalner receives FDA approval, the company plans to commercialize its lead candidate for epilepsy and depression indications. Revenue will come from prescription drug sales through pharmacy channels.

xenon-pharma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Xenon Pharmaceuticals is a clinical-stage neuroscience biopharmaceutical company developing proprietary small-molecule ion channel modulators for neurological and psychiatric disorders. Its lead candidate, azetukalner, is a first-in-class KV7 potassium channel opener in Phase 3 trials for focal onset seizures, generalized tonic-clonic seizures, major depressive disorder, and bipolar depression, with a planned FDA New Drug Application in Q3 2026. The pipeline also includes Phase 1 candidates XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain), plus the partnered NBI-921355 sodium channel inhibitor program with Neurocrine Biosciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 53.2% median reduction in monthly seizure frequency at 25mg dose vs 10.4% for placebo (p<0.0001)
+4 more records
Product overview1 text field

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing a pipeline of ion channel modulators for neurological and psychiatric disorders. The company's lead product candidate is azetukalner (XEN1101), a KV7 potassium channel opener in Phase 3 clinical trials for focal onset seizures (X-TOLE2, X-TOLE3), generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar depression (X-CEED). The early-stage pipeline includes XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain) in Phase 1, plus partnered program NBI-921355 with Neurocrine Biosciences. The company operates from offices in Vancouver, British Columbia and Boston, Massachusetts.

Product and service4 records
1Azetukalner (XEN1101)
CategoryDrug Candidate
Description

Novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for focal onset seizures, generalized tonic-clonic seizures, major depressive disorder, and bipolar depression; if approved, would be the only potassium channel opener among antiseizure medications.

2XEN1120
CategoryDrug Candidate
Description

KV7 potassium channel opener in Phase 1 development for pain indications, leveraging Xenon's ion channel chemistry platform.

3XEN1701
CategoryDrug Candidate
Description

Selective NaV1.7 sodium channel inhibitor in Phase 1 development for pain, leveraging Xenon's extensive NaV1.7 human genetics and pain research heritage.

4NBI-921355
CategoryPartnered Program
Description

Selective NaV1.2/1.6 sodium channel inhibitor for epilepsy partnered with Neurocrine Biosciences, currently in Phase 1 clinical trials.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Strategic partnership established in 2020 to develop selective sodium channel inhibitors for epilepsy. The partnered program NBI-921355 (NaV1.2/1.6 Inhibitor) is currently in Phase 1 clinical trials for epilepsy. This collaboration leverages Xenon's ion channel expertise with Neurocrine's development and commercialization capabilities.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large established CNS biopharma with a deep epilepsy portfolio (Keppra, Vimpat, Briviact). Sets the standard for ASM competition that any new epilepsy entrant like azetukalner must displace.

TypeDirect peer
Description

Clinical-stage CNS biopharma with Zurzuvae (zuranolone) approved for postpartum depression and prior work in epilepsy/seizure disorders. Directly comparable as a small, focused CNS developer commercializing a first-in-class neuropsychiatric mechanism.

TypeDirect peer
Description

Specialty CNS biopharma focused on seizure disorders with Ztalmy (ganaxolone) approved for CDKL5 deficiency disorder and in trials for refractory status epilepticus. Most directly comparable commercial-stage epilepsy specialist to Xenon.

TypeDirect peer
Description

CNS specialty pharma commercializing branded antiseizure and movement disorder products (Oxtellar XR, Trokendi XR, Apokyn). Closely aligned as a smaller commercial-stage neurology company targeting the same epilepsy and adjacent CNS prescriber base.

TypeEmerging player
Description

Clinical-stage CNS developer with lead programs in severe epilepsy syndromes including Dravet syndrome. Comparable as a small-cap, CNS-focused epilepsy developer competing for the same patient and prescriber audiences as Xenon.

TypeDirect peer
Description

Developer and commercializer of cenobamate (Xcopri) for focal-onset seizures. Direct competitor in the partial-onset epilepsy space that azetukalner will also target.

TypeBroad incumbent
Description

Global specialty biopharma with major CNS/epilepsy franchise including Xywav/Epidiolex (acquired via GW Pharmaceuticals for $7.2B). A larger established player in the same epilepsy/CNS commercial arena.

TypeBroad incumbent
Description

Established CNS biopharma and Xenon's 2020 sodium channel collaboration partner for NBI-921355. Comparable as a large CNS-focused commercial-stage company with overlapping ion channel and neurology R&D interests.

TypeBroad incumbent
Description

CNS specialty biopharma with commercial products in neurology/psychiatry (e.g., Daybue, Nuplazid). Comparable as a focused CNS commercializer competing for the same specialty neurologist and psychiatrist audiences.

TypeBroad incumbent
Description

Major neurology-focused biopharma with established CNS portfolio and a depression pipeline (Zurzuvae commercialized with Sage). Relevant incumbent for any potential strategic interest in Xenon.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xenon Pharmaceuticals

Neurology Pharmaceuticalsxenon-pharma.com

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders, with lead candidate azetukalner in Phase 3 trials for epilepsy and depression ahead of a planned 2026 FDA submission.

What Xenon Pharmaceuticals does

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for neurological and psychiatric disorders. Founded in 1996 and headquartered in Burnaby, British Columbia, with a U.S. office in Needham, Massachusetts, the company trades on NASDAQ under the ticker XENE following its 2014 U.S. IPO. Xenon leverages decades of research in human genetics and ion channel biology to develop a pipeline of small molecule modulators targeting potassium (KV7) and sodium (NaV) channels in the central and peripheral nervous systems.

The company's lead product candidate is azetukalner (XEN1101), a novel, potent KV7 potassium channel opener currently in Phase 3 clinical trials across multiple indications including focal onset seizures (X-TOLE2/X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2/X-NOVA3), and bipolar depression (X-CEED). Positive Phase 3 X-TOLE2 results announced in March 2026 demonstrated 53.2% median reduction in monthly seizure frequency at the 25mg dose versus 10.4% for placebo, positioning azetukalner as a potential first-in-class potassium channel opener among antiseizure medications. The early-stage pipeline includes XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain) in Phase 1, plus the partnered program NBI-921355 (NaV1.2/1.6 inhibitor) developed with Neurocrine Biosciences.

As a pre-commercial company, Xenon does not yet generate product revenue and funds operations through equity financings. Cumulative disclosed public offerings total over $1.7 billion across 2021–2026, most recently a $747.5 million upsized offering in March 2026 that valued the company at approximately $5.3 billion. The planned FDA New Drug Application submission in Q3 2026 is the binary catalyst for transitioning to commercial revenue, supported by an active commercial infrastructure buildout including a Chief Commercial Officer (June 2025), Chief Financial Officer (October 2025), and Chief Operating Officer (August 2024). Distribution is expected to flow through specialty pharmacies, hospital buying groups, and retail networks, with Medical Science Liaisons engaging epileptologists and psychiatrists ahead of launch.

Xenon Pharmaceuticals firmographics

Firmographics
Name
Xenon Pharmaceuticals
Legal name
Xenon Pharmaceuticals Inc.
Website
https://xenon-pharma.com
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
251–500 employees
Short description
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders, with lead candidate azetukalner in Phase 3 trials for epilepsy and depression ahead of a planned 2026 FDA submission.
Ownership category
akta.pro rank

Xenon Pharmaceuticals industry classification

Industry
Product category
Neurology Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neuroscience drug development
  • Ion channel modulators
  • Epilepsy therapeutics
  • Potassium channel openers
  • Central nervous system pharmaceuticals

Where Xenon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Burnaby
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Xenon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue company. Once azetukalner receives FDA approval, the company plans to commercialize its lead candidate for epilepsy and depression indications. Revenue will come from prescription drug sales through pharmacy channels.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Xenon Pharmaceuticals product offering

Product offering

Core offering

Xenon Pharmaceuticals is a clinical-stage neuroscience biopharmaceutical company developing proprietary small-molecule ion channel modulators for neurological and psychiatric disorders. Its lead candidate, azetukalner, is a first-in-class KV7 potassium channel opener in Phase 3 trials for focal onset seizures, generalized tonic-clonic seizures, major depressive disorder, and bipolar depression, with a planned FDA New Drug Application in Q3 2026. The pipeline also includes Phase 1 candidates XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain), plus the partnered NBI-921355 sodium channel inhibitor program with Neurocrine Biosciences.

Product overview

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing a pipeline of ion channel modulators for neurological and psychiatric disorders. The company's lead product candidate is azetukalner (XEN1101), a KV7 potassium channel opener in Phase 3 clinical trials for focal onset seizures (X-TOLE2, X-TOLE3), generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar depression (X-CEED). The early-stage pipeline includes XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain) in Phase 1, plus partnered program NBI-921355 with Neurocrine Biosciences. The company operates from offices in Vancouver, British Columbia and Boston, Massachusetts.

Differentiator

Problem solved

Functional benefit

Products and services

  • Azetukalner (XEN1101) Novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for focal onset seizures, generalized tonic-clonic seizures, major depressive disorder, and bipolar depression; if approved, would be the only potassium channel opener among antiseizure medications.
  • XEN1120 KV7 potassium channel opener in Phase 1 development for pain indications, leveraging Xenon's ion channel chemistry platform.
  • XEN1701 Selective NaV1.7 sodium channel inhibitor in Phase 1 development for pain, leveraging Xenon's extensive NaV1.7 human genetics and pain research heritage.
  • NBI-921355 Selective NaV1.2/1.6 sodium channel inhibitor for epilepsy partnered with Neurocrine Biosciences, currently in Phase 1 clinical trials.

Quantifiable outcome

  • 53.2% median reduction in monthly seizure frequency at 25mg dose vs 10.4% for placebo (p<0.0001)
  • +4 more outcomes

Companies that use Xenon Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Xenon Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Xenon Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Neurocrine BiosciencescoreStrategic or Co-development Partner · 1 January 2020Strategic partnership established in 2020 to develop selective sodium channel inhibitors for epilepsy. The partnered program NBI-921355 (NaV1.2/1.6 Inhibitor) is currently in Phase 1 clinical trials for epilepsy. This collaboration leverages Xenon's ion channel expertise with Neurocrine's development and commercialization capabilities.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Xenon Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • UCB: Large established CNS biopharma with a deep epilepsy portfolio (Keppra, Vimpat, Briviact). Sets the standard for ASM competition that any new epilepsy entrant like azetukalner must displace.
  • Jazz Pharmaceuticals: Global specialty biopharma with major CNS/epilepsy franchise including Xywav/Epidiolex (acquired via GW Pharmaceuticals for $7.2B). A larger established player in the same epilepsy/CNS commercial arena.
  • Neurocrine Biosciences: Established CNS biopharma and Xenon's 2020 sodium channel collaboration partner for NBI-921355. Comparable as a large CNS-focused commercial-stage company with overlapping ion channel and neurology R&D interests.
  • Acadia Pharmaceuticals: CNS specialty biopharma with commercial products in neurology/psychiatry (e.g., Daybue, Nuplazid). Comparable as a focused CNS commercializer competing for the same specialty neurologist and psychiatrist audiences.
  • Biogen: Major neurology-focused biopharma with established CNS portfolio and a depression pipeline (Zurzuvae commercialized with Sage). Relevant incumbent for any potential strategic interest in Xenon.

Direct peers

  • Sage Therapeutics: Clinical-stage CNS biopharma with Zurzuvae (zuranolone) approved for postpartum depression and prior work in epilepsy/seizure disorders. Directly comparable as a small, focused CNS developer commercializing a first-in-class neuropsychiatric mechanism.
  • Marinus Pharmaceuticals: Specialty CNS biopharma focused on seizure disorders with Ztalmy (ganaxolone) approved for CDKL5 deficiency disorder and in trials for refractory status epilepticus. Most directly comparable commercial-stage epilepsy specialist to Xenon.
  • Supernus Pharmaceuticals: CNS specialty pharma commercializing branded antiseizure and movement disorder products (Oxtellar XR, Trokendi XR, Apokyn). Closely aligned as a smaller commercial-stage neurology company targeting the same epilepsy and adjacent CNS prescriber base.
  • SK Life Science: Developer and commercializer of cenobamate (Xcopri) for focal-onset seizures. Direct competitor in the partial-onset epilepsy space that azetukalner will also target.

Emerging players

  • Longboard Pharmaceuticals: Clinical-stage CNS developer with lead programs in severe epilepsy syndromes including Dravet syndrome. Comparable as a small-cap, CNS-focused epilepsy developer competing for the same patient and prescriber audiences as Xenon.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Xenon Pharmaceuticals social profiles

Digital presence

Xenon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xenon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles16 records

Xenon Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Xenon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xenon Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xenon Pharmaceuticals

What does Xenon Pharmaceuticals do?

Xenon Pharmaceuticals is a clinical-stage neuroscience biopharmaceutical company developing proprietary small-molecule ion channel modulators for neurological and psychiatric disorders. Its lead candidate, azetukalner, is a first-in-class KV7 potassium channel opener in Phase 3 trials for focal onset seizures, generalized tonic-clonic seizures, major depressive disorder, and bipolar depression, with a planned FDA New Drug Application in Q3 2026. The pipeline also includes Phase 1 candidates XEN1120 (KV7 for pain) and XEN1701 (NaV1.7 for pain), plus the partnered NBI-921355 sodium channel inhibitor program with Neurocrine Biosciences.

Is Xenon Pharmaceuticals a public or private company?

Xenon Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Xenon Pharmaceuticals founded?

Xenon Pharmaceuticals was founded in 1996. It employs 251 to 500 people.

Where is Xenon Pharmaceuticals based?

Xenon Pharmaceuticals is headquartered in Burnaby, Canada, in the North America region.

How does Xenon Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Xenon Pharmaceuticals's main competitors?

Broad incumbents on record are UCB, Jazz Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals and Biogen. Direct peers are Sage Therapeutics, Marinus Pharmaceuticals, Supernus Pharmaceuticals and SK Life Science. Longboard Pharmaceuticals is listed as an emerging player.

Does Xenon Pharmaceuticals have an API?

No public API is recorded for Xenon Pharmaceuticals.

What industry is Xenon Pharmaceuticals in?

Xenon Pharmaceuticals's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldReviewing Senti Biosciences (NASDAQ:SNTI) and Xenon Pharmaceuticals (NASDAQ:XENE)Senti Biosciences and Xenon Pharmaceuticals are compared on valuation, earnings, and analyst ratings. Xenon beats Senti on 8 of 14 factors, with a lower P/E ratio and higher institutional ownership. Analysts see Senti with a 10,244% upside versus Xenon's 88%.American Banking and Market NewsContrasting Senti Biosciences (NASDAQ:SNTI) and Xenon Pharmaceuticals (NASDAQ:XENE)Senti Biosciences and Xenon Pharmaceuticals are compared on valuation, profitability, and analyst ratings. Xenon trades at a lower P/E ratio and has higher institutional ownership, while Senti has higher earnings and a higher price target. Analysts favor Senti due to its higher probable upside.TradingViewJP Morgan maintains Xenon Pharmaceuticals at Overweight, lowers price target to $80 from $82JP Morgan maintained Xenon Pharmaceuticals at Overweight and lowered its price target to $80 from $82. The target implies an upside of 103.8% from the Nov 16 close of $39.26.Simply Wall StHow Wider Losses At Xenon Pharmaceuticals (XENE) Have Changed Its Investment StoryXenon Pharmaceuticals reported a Q3 2026 net loss of $110.44 million and a nine-month loss of $323.47 million. The company filed an ESOP-related shelf registration for 300,000 shares, signaling ongoing cash needs. Analysts project revenue of $435.9 million and earnings of $75.0 million by 2029.Investing.comXenon at Stifel 2026 healthcare conference: epilepsy launch in focusXenon Pharmaceuticals outlined its strategy at the Stifel 2026 Healthcare Conference, focusing on azetukalner for epilepsy with a possible early-2028 launch. The company will unblind its Phase III MDD study in December and expects two pain candidates to enter Phase II in 2025. Management cited $1.2 billion in cash, sufficient through 2029.Investing.comXenon Pharmaceuticals at Guggenheim conference: launch plans take shapeXenon Pharmaceuticals outlined its first commercial launch plan at the Guggenheim conference, targeting early 2028 for azetukalner in focal seizures after FDA approval. The company holds $1.2 billion in cash, giving it runway into 2029, and paused depression studies due to neuropsychiatric adverse events. It also advanced three pain programs with Phase 2 studies expected in 2025.Simply Wall StXenon Pharmaceuticals (XENE) Stock Looks Above Fair Value Next To Book ValueXenon Pharmaceuticals has returned 36.2% over three years, trading at a P/B of 3.2x versus the biotech industry average of 1.8x. The company's azetukalner NDA filing and pain candidates moving toward Phase 2 justify a premium, but the neuroscience portfolio and funding needs remain key.The Motley FoolXenon (XENE) Q3 2026 Earnings Call TranscriptXenon Pharmaceuticals reported a Q3 2026 net loss of $110.4 million and $1.2 billion in cash, with management expecting operations to be funded into 2029. The company submitted its New Drug Application for azetukalner for focal seizures in September 2026, and expects top-line data for its major depressive disorder study in December 2026.The Motley FoolXenon (XENE) Q3 2026 Earnings Call TranscriptXenon Pharmaceuticals reported a Q3 2026 net loss of $110.4 million and $1.2 billion in cash, with management expecting operations to be funded into 2029. The company submitted its New Drug Application for azetukalner for focal seizures in September 2026, and expects top-line data for its major depressive disorder study in December 2026.YahooXenon Pharmaceuticals Inc (XENE) (Q3 2026) Earnings Call Highlights: $1. ...Xenon Pharmaceuticals reported Q3 2026 with $1.2 billion in cash and a runway to 2029. The company submitted azetukalner's NDA for focal seizures, with X-TOLE2 showing a 42.7% placebo-adjusted median percent change. It paused neuropsychiatry enrollment after adverse events, with top-line X-NOVA2 data expected in December 2026.